Pharmaceutical company focusing on advancing psychedelics therapies by utilizing drug discovery platforms and innovative drug delivery Cybin Inc. (NYSE American: CYBN) announced having secured an approval from U.S Food and Drug Administration (FDA) for its neuroimaging device that helps researchers to quantify the effects of psychedelics on the brain in real-time.
The neuroimaging device is called Kernel Flow and it was developed by Cybin in partnership with neurotech company Kernel. The device is set to be used in a feasibility study to find out ketamine’s effect on the brain specifically cerebral cortex hemodynamics.
This device goes down as the first of its kind leveraging on neuroimaging to measure the activity of brain in real-time using a wearable helmet which looks like a bicycle helmet during psychedelics therapies.
This announcement was made by the company’s chief clinical officer, Dr. Alex Belser, who believes the study of ketamine’s psychedelic effects while wearing the neuroimaging device equipped with sensors to record brain activity could open up new frontiers of understanding.
“Conventional neuroimaging just isn’t dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding,” said Belser.
